**武春燕**

主任医师

南昌大学硕士生导师

* **招生专业**

肿瘤学

* **现任职务及专业学术任职**

同济大学附属上海市肺科医院病理科主任，中华医学会病理学分会胸部疾病学组委员、中华医学会病理学分会分子病理学组委员、中华医学会结核病学分会病理专业委员会主任委员、中国研究型医院学会病理学委员会胸肺学组副组长、上海市临床病理质量控制中心细胞病理工作组专家、上海市临床病理质量控制胸部病理工作组专家，《中华病理学》杂志编委。

* **研究方向**

肺部疾病的组织形态学、分子病理及相关肿瘤耐药机制和分子标志物方面的临床研究及基础转化研究

* **科研业绩**

擅长肺癌、间皮瘤、结核和结节病、间质性肺疾病、职业性尘肺、胸腺瘤等疾病的病理诊断。主持国家自然科学基金、上海市自然科学基金、上海市科委项目、上海市申康医院发展中心项目等6项课题。发表SCI收录论文40余篇。参编《肺部肿瘤学》《临床病理诊断与鉴别诊断》等多部著作。参与制定常规免疫组织化学初筛ALK阳性非小细胞肺癌、中国非小细胞肺癌患者表皮生长因子受体基因突变检测、中国结核病病理学诊断、非小细胞肺癌新辅助治疗疗效病理评估专家共识及肺肉芽肿性疾病病理诊断原则及流程专家建议等多项专家共识。作为主要完成人分别荣获国家教育部科学进步二等奖、上海市抗癌科技奖一等奖及上海医学科技奖二等奖等奖项。

* **团队简介**

武春燕教授团队，致力于胸肺部疾病的临床病理研究及转化应用。团队在肺癌耐药机制、分子病理学、智能诊断及肺癌高危因素等方面展开了一系列研究，推动了学科的发展，在业界内产生了广泛的影响。团队立足于学科发展的前沿，积极推动新理念和新技术的临床应用和相关临床试验的开展，专注于培养学科人才，使学科影响力达到国内领先水平。

* **主要论著**
1. Xie X, Fu CC, Lv L, Ye Q, Yu Y, Fang Q, Zhang L, Hou L, **Wu C**. Deep convolutional neural network-based classification of cancer cells on cytological pleural effusion images. Mod Pathol. 2022 May;35(5):609-614.
2. Hou L, Wang T, Chen D, She Y, Deng J, Yang M, Zhang Y, Zhao M, Zhong Y, Ma M, Zhao G, Chen Y, Xie D, Zhu Y, Chen Q, **Wu C\***, Chen C\*; Multi-omics Classifier for Pulmonary Nodules (MISSION) Collaborative Group. Prognostic and predictive value of the newly proposed grading system of invasive pulmonary adenocarcinoma in Chinese patients: a retrospective multicohort study. Mod Pathol. 2022 Jun;35(6):749-756.
3. Zhao J, Sun L, Sun K, Wang T, Wang B, Yang Y, **Wu C\***, Sun X\*. Development and Validation of a Radiomics Nomogram for Differentiating Pulmonary Cryptococcosis and Lung Adenocarcinoma in Solitary Pulmonary Solid Nodule. Front Oncol. 2021 Nov 9;11:759840.
4. Ma YS, Hou LK, Yao SH, Liu JB, Yu XC, Shi Y, Yang XL, Wu W, **Wu CY\***, Jiang GX\*, Fu D\*. Elevated Stratifin promotes cisplatin-based chemotherapy failure and poor prognosis in non-small cell lung cancer. Mol Ther Oncolytics. 2021 Jul 21;22:326-335.
5. Guo J, Hou L, Zhang W, Dong Z, Zhang L, **Wu C**. Improving differential diagnosis of pulmonary large cell neuroendocrine carcinoma and small cell lung cancer via a transcriptomic, biological pathway-based machine learning model. Transl Oncol. 2021 Dec;14(12):101222.
6. Zhou F, Huang Y, Cai W, Li J, Su C, Ren S, **Wu C\***, Zhou C\*. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients. Lung Cancer. 2021 Mar;153:66-72.
7. Chen J, Tan Y, Sun F, Hou L, Zhang C, Ge T, Yu H, Wu C, Zhu Y, Duan L, Wu L, Song N, Zhang L, Zhang W, Wang D, Chen C, **Wu C\***, Jiang G\*, Zhang P\*. Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer. Genome Biol. 2020 Jun 24;21(1):152.
8. Wu W, Huang Y, Guo J, Xie X, Li H, Cao Z, Wei H, **Wu C**. Detection and comparison of EGFR mutations from supernatants that contain cell-free DNA and cell pellets from FNA non-small cell lung cancer specimens. Cancer Cytopathol. 2020 Aug;128(8):545-552.
9. Jiang T, Shi J, Dong Z, Hou L, Zhao C, Li X, Mao B, Zhu W, Guo X, Zhang H, He J, Chen X, Su C, Ren S, **Wu C\***, Zhou C\*. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. J Hematol Oncol. 2019 Jul 12;12(1):75.
10. Ma YS, Yu F, Zhong XM, Lu GX, Cong XL, Xue SB, Xie WT, Hou LK, Pang LJ, Wu W, Zhang W, Cong LL, Liu T, Long HD, Sun R, Sun HY, Lv ZW, **Wu CY\***, Fu D\*. miR-30 Family Reduction Maintains Self-Renewal and Promotes Tumorigenesis in NSCLC-Initiating Cells by Targeting Oncogene TM4SF1. Mol Ther. 2018 Dec 5;26(12):2751-2765.
11. Yu F, Liu JB, Wu ZJ, Xie WT, Zhong XJ, Hou LK, Wu W, Lu HM, Jiang XH, Jiang JJ, Cao ZY, Cong GJ, Shi MX, Jia CY, Lu GX, Song YC, Chai L, Lv ZW, **Wu CY\***, Ma YS\*, Fu D\*. Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14. Cancer Lett. 2018 Jul 28;427:74-84.